№ lp_2_3_62727
File format: docx
Character count: 7264
File size: 2587 KB
The document provides detailed insights into the expression profiles of immune checkpoint genes (ICGs) and their potential roles in predicting the response to immunotherapy in cancer patients.
Year:
2023
Region / City:
Wuhan, China
Topic:
Immunology, Cancer Research, Gene Expression, Immunotherapy
Document Type:
Research Article
Institution:
Wuhan University of Science & Technology, Huazhong University of Science and Technology, Anhui Normal University
Authors:
Fei-Fei Hu, Chun-Jie Liu, Lan-Lan Liu, Qiong Zhang, An-Yuan Guo
Target Audience:
Researchers, Healthcare Professionals, Academics in Immunology and Oncology
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / city:
Canadian Ski Marathon
Theme:
Checkpoint operations, volunteer duties, and event coordination
Document type:
Manual
Organization / institution:
Canadian Ski Marathon
Author:
CSM Event Director, CSM Admin-2
Target audience:
Event leaders, checkpoint/task leaders, volunteers
Period of validity:
February 6-8, 2026
Approval date:
N/A
Modification date:
N/A
Year:
2019
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme, PD-(L)1 inhibitors, non-small cell lung cancer (NSCLC)
Document type:
Meeting minutes
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Professor Andrew Wilson (PBAC Chair)
Target audience:
Stakeholders in the healthcare and pharmaceutical industry
Period of validity:
2019 and onwards
Date of approval:
February 2019
Date of amendments:
Not specified
Year:
2026
Region / City:
N/A
Theme:
American Sign Language Assessment
Document Type:
Examination
Institution:
N/A
Author:
N/A
Target Audience:
Students of American Sign Language
Validity Period:
N/A
Approval Date:
June 22, 2026
Modification Date:
N/A
Date:
June 24, 2025
Region / City:
Hemet, California, United States
Topic:
Road safety and impaired driving enforcement
Document Type:
Press release / public safety announcement
Organization:
Hemet Police Department
Prepared by:
Sergeant M. Chavez
Contact Person:
Sergeant Matt Chavez
Contact Phone:
(951) 765-2400
Contact Email:
[email protected]
Media Contact:
Public Information Social Media Officer Judith Gibson
Media Contact Email:
[email protected]
Event Date:
July 11, 2025
Event Time:
8:00 pm – 2:00 am
Event Type:
DUI and Driver’s License Checkpoint
Location:
Undisclosed location within the City of Hemet
Funding Source:
California Office of Traffic Safety grant through the National Highway Traffic Safety Administration
Target Audience:
Drivers and residents of the City of Hemet
Subject Details:
Enforcement of laws related to driving under the influence of alcohol, drugs, prescription medication, and marijuana
Year:
2018
Region:
Australia
Subject:
PD-1 and PD-L1 checkpoint inhibitor immunotherapies
Document Type:
Submission Template
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Intended Audience:
Patients, healthcare providers, researchers, pharmaceutical industry, government bodies
Submission Deadline:
29 June 2018
Contact Information Required:
Yes
Confidentiality Note:
Commercial-in-confidence or personal information to be redacted before publication
Format:
Electronic submission in Microsoft Word or text-based format
Questions Covered:
Advantages, disadvantages, unmet clinical need, evidence requirements, cost-effectiveness, subsidy pricing, biomarker considerations, extrapolation across medicines and cancer types, rare cancers, follow-up actions, clinical trials, international models
Year:
2019–2024
Region:
International
Topic:
Oncology / Hepatocellular Carcinoma
Document Type:
Meta-analysis
Institution:
Multiple clinical research centers
Authors:
Various (from included RCTs)
Target Audience:
Medical researchers, oncologists, clinicians
Study Design:
Randomized controlled trials, Phase II and III
Interventions:
Nivolumab, Pembrolizumab, Atezolizumab, Sintilimab
Comparators:
Placebo, standard care, active surveillance
Outcomes Measured:
Overall survival (OS), Recurrence-free survival (RFS), adverse events (AEs)
Sample Size:
Data pooled from 10 studies
Statistical Methods:
DerSimonian-Laird random-effects model, hazard ratios (HRs), risk ratios (RRs)
Adverse Events Reported:
Fatigue, hypertension, elevated liver enzymes (grade 3+)
Publication Type:
Peer-reviewed articles
Description:
Systematic review and meta-analysis of clinical trials assessing survival outcomes and safety of adjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma after curative treatment.
Year:
2021
Region / city:
Not specified
Topic:
Resource multiplexing between child and parent links of IAB node
Document type:
Contribution
Organization:
3GPP TSG RAN WG1
Author:
Moderator (AT&T)
Target audience:
3GPP members, stakeholders in telecommunications standards
Period of validity:
January 25th – February 5th, 2021
Approval date:
Not specified
Amendment date:
Not specified
Summary:
This document provides a summary of various proposals for improving resource multiplexing between the child and parent links of an IAB node, particularly focused on simultaneous operations, frequency domain multiplexing, and operational resource configurations.
Year:
2021
Organization:
3GPP TSG RAN WG1
Document type:
Technical contribution
Source:
Moderator (AT&T)
Title:
Summary of [104-e-NR-eIAB-01] – 1st Checkpoint
Agenda item:
8.10.1
Scope:
Enhancements to resource multiplexing between child and parent links of an IAB node
Contributors:
Huawei, Vivo, Intel, CEWiT, IITM, IITH, Tejas Networks, Reliance Jio
Target audience:
RAN working group members
Checkpoint dates:
Jan 27, Feb 5, Feb 13
Topics covered:
Simultaneous operation of access and backhaul links, dual-connectivity, TDD configurations, resource allocation strategies
Year:
2014
Software Version:
vCO 5.5.2, vRO HTTP REST Plugin 1.0.7
Region:
Global
Document Type:
Installation and Configuration Guide
Author:
VMware / CheckPoint
Target Audience:
System administrators, IT engineers
Required Environment:
vCenter 5.5.0, Windows client for vCO, CheckPoint Management Server
Procedures Included:
OVF deployment, password setup, network configuration, SSL certificate import, SSO authentication, plugin installation, workflow execution
Troubleshooting Notes:
Password issues, SSL key errors, time synchronization
Workflow Examples:
Add Host, Add Host to Group, Add Access Rule, Install Policy
Year:
2023
Region / City:
Europe
Topic:
Allergen immunotherapy, allergic asthma, house dust mites
Document Type:
Clinical guideline
Organization / Institution:
European Academy of Allergy and Clinical Immunology (EAACI)
Authors:
I Agache, S Lau, CA Akdis, S Smolinska, M Bonini, O Cavkaytar, B Flood, P Gajdanowicz, K Izuhara, Ö Kalayci, R Mosges, O Palomares, N Papadopoulos, M Sokolowska, E Angier, M Fernandez-Rivas, G Pajno, O Pfaar, G Roberts, D Ryan, G Sturm, R van Ree, EM Varga, R Gerth van Wijk, JJ Yepes – Nuñez, M Jutel
Target Audience:
Healthcare professionals (doctors, researchers, allergy specialists)
Date Approved:
2023
Date of Revisions:
N/A
Year:
Not specified
Region / City:
Not specified
Topic:
Allergen immunotherapy billing and insurance coverage
Document Type:
Template
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Healthcare providers, insurance companies
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Organization:
Society for Immunotherapy of Cancer
Document Type:
Bibliography
Subject:
Cancer Immunotherapy
Focus:
Head and Neck Squamous Cell Carcinoma
Publication Date:
December 17, 2018
Date Range of Literature Search:
December 1, 2013 – December 17, 2018
Search Limits:
Humans, Clinical Trial, Meta-Analysis, Practice Guideline, Randomized Controlled Trial, Review
Therapeutic Agents Covered:
Pembrolizumab, Nivolumab, Cemiplimab, Durvalumab
Biomarkers and Targets:
PD-1, PD-L1, HPV
Total References Identified:
199
Total Duplicates Removed:
42
Total Records in Bibliography:
157
Topics Included:
Immune checkpoint inhibitors, biomarkers, combination immunotherapy, adverse events, toxicity, vaccine, adjuvant and neoadjuvant immunotherapy, rare head and neck cancers
Journal:
World Journal of Gastrointestinal Oncology
Manuscript Number:
80135
Manuscript Type:
Review
Authors:
Ying-Zhe Luo; Hong Zhu
Author Affiliations:
Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Corresponding Author:
Hong Zhu
Funding:
The Key Research Projects of Science and Technology of Sichuan Province (No. 2022YFS0189)
Received:
September 18, 2022
Revised:
February 11, 2023
Accepted:
February 27, 2023
Published Online:
March 15, 2023
Volume and Issue:
Volume 15, Issue 3
Pages:
405-424
DOI:
10.4251/wjgo.v15.i3.405
Publisher:
Baishideng Publishing Group Inc.
Keywords:
Recurrent hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitor; Chimeric antigen receptor-engineered T cell; Oncolytic virus; Tumor vaccine
Subject Area:
Oncology; Hepatology; Cancer Immunotherapy
Geographic Context:
Global epidemiology with reference to East and South-East Asia, United States, and Europe
Year:
2026
Region / City:
International / Multiple research institutions
Subject:
Cancer immunotherapy, tumor microenvironment
Document type:
Supplementary scientific data
Institution:
University of Southampton, Genkyotex SA, La Jolla Institute for Allergy & Immunology, University of Toronto, University of Kent
Authors:
Kirsty Ford, Christopher J. Hanley, Massimiliano Mellone, Cedric Szyndralewiez, Freddy Heitz, Philippe Wiesel, Oliver Wood, Maria Machado, Monette Lopez, Anusha-Preethi Ganesan, Chuan Wang, Ankur Chakravarthy, Tim Fenton, Emma V. King, Pandurangan Vijayanand, Christian H. Ottensmeier, Aymen Al-Shamkhani, Natalia Savelyeva, Gareth J. Thomas
Target audience:
Researchers in oncology and immunology
Data type:
Figures, tables, and experimental results
Methods:
Q-PCR, immunofluorescence, IHC, RNA sequencing, gene network analysis
Experimental models:
Murine syngeneic tumors, TC1, MC38, 4T1, BALBneuT breast tumors
Treatment tested:
NOX4 inhibition, TGF-β1 inhibition, αPD-1, αCTLA-4, macrophage depletion
Key focus:
CAF-mediated CD8 T-cell exclusion, tumor growth modulation, immunotherapy response
Supplementary content:
Figures S1–S6, Tables S1–S2
Year:
2022
Region / City:
Daejeon, Republic of Korea
Subject:
Pharmacology, Immunotherapy, Herbal Medicine
Document Type:
Supplementary Research Document
Institution:
Chungnam National University, Korea Institute of Oriental Medicine
Authors:
Sung-yoon Yang, Jin-Mu Yi, Jaemoo Chun, Seongwon Park, Tham Thi Bui, Hwi-yeol Yun, Jung-woo Chae, Mi-Kyung Jeong
Target Audience:
Researchers in pharmacology and immunotherapy
Methodologies:
LC-MS/MS, ELISA, Cytokine Assay
Compounds Analyzed:
Bojungikki-tang components, anti-PD-L1 antibody
Study Model:
Mouse serum samples
Purpose:
Assessment of pharmacokinetic interactions and biomarker quantification
Note:
Prescribing Physician
Vials:
D, E, F
Vaccine Abbreviations:
T, M, G, C, W, D, R, Cr, Mx, Dm
Baseline Measurements:
Peak Flow, Blood Pressure
Health Screen:
Yes/No
Antihistamine Use:
Yes/No
Reactions:
Local (LR), Systemic (SR)
Year:
2026
Region / City:
Shanghai, China
Topic:
Cancer immunotherapy, ovarian cancer
Document Type:
Research article with supplementary materials
Institution:
Fudan University, Obstetrics and Gynecology Hospital; Shanghai Cancer Center
Authors:
Kankan Cao, Guodong Zhang, Moran Yang, Yiying Wang, Mengdi He, Chen Zhang, Yan Huang, Jiaqi Lu, Haiou Liu
Target Audience:
Biomedical researchers, oncologists
Experimental Models:
Mouse xenografts and isografts (OVCAR-5, SKOV3, HM1, ID8agg)
Methodologies:
RNA sequencing, CCK-8 proliferation assay, BrdU incorporation, colony formation assay, migration assay, Random Forest analysis, scRNA-seq
Therapeutic Interventions:
St3gal3 inhibition, macrophage depletion, CXCR3 blocking, α2,3 sialylation targeting, dual immune checkpoint blockade (anti-PD-1, anti-CTLA-4)
Data Repositories:
GEO accession numbers GSE213219, GSE224856, GSE158937, GSE147082
Supplementary Materials:
Figures S1–S14, detailed methods, references
Year:
2020
Region / City:
Bowdoinham, Maine
Subject:
Development, Urban Planning
Document Type:
Research Paper
Organization / Institution:
Bowdoinham Town Government
Author:
Rodger Heidgerken
Target Audience:
Local Government Officials, Urban Planners
Period of Validity:
2011-2024
Approval Date:
N/A
Modification Date:
N/A
Note:
Year
Author:
Andreas Fønss Møller, Kedar Nath Natarajan
Year:
2026
Region / City:
N/A
Topic:
Astronomy
Document Type:
Educational Material
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Students, Educators
Period of Action:
N/A
Approval Date:
N/A
Date of Changes:
N/A